Brief: Tuhura Biosciences Enters Into Exclusivity And Right Of First Offer Agreement For Kineta's KVA12123 Novel Anti-Vista Checkpoint Inhibitor
08/07/2024 11:42
July 8 (Reuters) - Kintara Therapeutics Inc KTRA.O :
* TUHURA BIOSCIENCES ENTERS INTO EXCLUSIVITY AND RIGHT OF
FIRST
OFFER AGREEMENT FOR KINETA, INC.'S KVA12123 NOVEL ANTI-VISTA
CHECKPOINT INHIBITOR
* KINTARA THERAPEUTICS INC - UNDER TERMS OF AGREEMENT,
TUHURA WILL
PAY KINETA $5.0 MILLION
Source text for Eikon: ID:nPn2fm4jra
Further company coverage: KTRA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TuHURA Biosciences
See all newsBrief: Tuhura Biosciences Receives Key U.S. Patent For Its Groundbreaking Delta Opioid Receptor Antibody Drug Conjugate Technology
TuHURA Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tuhura Biosciences Reports Second Quarter 2026 Financial Results And Provides A Corporate Update
TuHURA Biosciences Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Tuhura Biosciences Inc Enters At The Market Offering Agreement With H.C. Wainwright & Co.